Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 467

1.

The Pituitary Is a Candidate Organ That Modulates Circulating Klotho Levels.

Sato T, Komaba H, Nagatani T, Watanabe T, Kishida Y, Fukagawa M.

J Endocr Soc. 2018 Nov 14;3(1):52-61. doi: 10.1210/js.2018-00223. eCollection 2019 Jan 1.

2.

Response to Comments on "Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study".

Akizawa T, Shimazaki R, Shiramoto M, Fukagawa M; Evocalcet Study Group.

Clin Drug Investig. 2019 Jan;39(1):109-111. doi: 10.1007/s40261-018-0737-y. No abstract available.

PMID:
30632107
3.

Decline in the Functional Status and Mortality in Patients on Hemodialysis: Results from the Japan Dialysis Outcome and Practice Patterns Study.

Matsuzawa R, Kamitani T, Roshanravan B, Fukuma S, Joki N, Fukagawa M.

J Ren Nutr. 2018 Dec 24. pii: S1051-2276(18)30252-8. doi: 10.1053/j.jrn.2018.10.012. [Epub ahead of print]

PMID:
30591357
4.

Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial.

J-DAVID Investigators, Shoji T, Inaba M, Fukagawa M, Ando R, Emoto M, Fujii H, Fujimori A, Fukui M, Hase H, Hashimoto T, Hirakata H, Honda H, Hosoya T, Ikari Y, Inaguma D, Inoue T, Isaka Y, Iseki K, Ishimura E, Itami N, Ito C, Kakuta T, Kawai T, Kawanishi H, Kobayashi S, Kumagai J, Maekawa K, Masakane I, Minakuchi J, Mitsuiki K, Mizuguchi T, Morimoto S, Murohara T, Nakatani T, Negi S, Nishi S, Nishikawa M, Ogawa T, Ohta K, Ohtake T, Okamura M, Okuno S, Shigematsu T, Sugimoto T, Suzuki M, Tahara H, Takemoto Y, Tanaka K, Tominaga Y, Tsubakihara Y, Tsujimoto Y, Tsuruya K, Ueda S, Watanabe Y, Yamagata K, Yamakawa T, Yano S, Yokoyama K, Yorioka N, Yoshiyama M, Nishizawa Y.

JAMA. 2018 Dec 11;320(22):2325-2334. doi: 10.1001/jama.2018.17749.

PMID:
30535217
5.

Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study.

Shigematsu T, Fukagawa M, Yokoyama K, Akiba T, Fujii A, Odani M, Akizawa T.

Clin Ther. 2018 Dec;40(12):2099-2111. doi: 10.1016/j.clinthera.2018.10.016. Epub 2018 Nov 23.

6.

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study.

Akizawa T, Shimazaki R, Fukagawa M; Evocalcet Study Group.

PLoS One. 2018 Oct 31;13(10):e0204896. doi: 10.1371/journal.pone.0204896. eCollection 2018.

7.

A Retrospective Study on Erythropoiesis Stimulating Agent Dose Reducing Potential of an Anti-Platelet Activation Membrane Dialyzer in Hemodialysis Patients.

Kakuta T, Ishida M, Komaba H, Suzuki H, Fukagawa M.

Ther Apher Dial. 2018 Oct 11. doi: 10.1111/1744-9987.12759. [Epub ahead of print]

PMID:
30311350
8.

Mineral and bone disorder management in hemodialysis patients: comparing PTH control practices in Japan with Europe and North America: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Yamamoto S, Karaboyas A, Komaba H, Taniguchi M, Nomura T, Bieber BA, De Sequera P, Christensson A, Pisoni RL, Robinson BM, Fukagawa M.

BMC Nephrol. 2018 Oct 5;19(1):253. doi: 10.1186/s12882-018-1056-5.

9.

Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan.

Shigematsu T, Shimazaki R, Fukagawa M, Akizawa T.

Clin Pharmacol. 2018 Sep 11;10:101-111. doi: 10.2147/CPAA.S171044. eCollection 2018.

10.

Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans.

Narushima K, Maeda H, Shiramoto M, Endo Y, Ohtsuka S, Nakamura H, Nagata Y, Uchimura T, Kannami A, Shimazaki R, Fukagawa M, Akizawa T.

Clin Transl Sci. 2019 Jan;12(1):20-27. doi: 10.1111/cts.12588. Epub 2018 Oct 24.

11.

Detection of Autonomic Nervous System Abnormalities in Diabetic Patients by 24-hour Ambulatory Blood Pressure Monitoring.

Kimura M, Toyoda M, Ono M, Saito N, Kaneyama N, Miyauchi M, Umezono T, Fukagawa M.

Tokai J Exp Clin Med. 2018 Sep 20;43(3):97-102.

12.

Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study.

Akizawa T, Shimazaki R, Shiramoto M, Fukagawa M; Evocalcet Study Group.

Clin Drug Investig. 2018 Oct;38(10):945-954. doi: 10.1007/s40261-018-0687-4.

13.

Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients.

Shigematsu T, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group.

Clin Exp Nephrol. 2019 Feb;23(2):258-267. doi: 10.1007/s10157-018-1635-6. Epub 2018 Aug 29.

PMID:
30159688
14.

TGF-Beta Signaling in Bone with Chronic Kidney Disease.

Iwasaki Y, Yamato H, Fukagawa M.

Int J Mol Sci. 2018 Aug 10;19(8). pii: E2352. doi: 10.3390/ijms19082352. Review.

15.

Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.

Fukagawa M, Shimazaki R, Akizawa T; Evocalcet study group.

Kidney Int. 2018 Oct;94(4):818-825. doi: 10.1016/j.kint.2018.05.013. Epub 2018 Jul 24.

16.

New Roles of Parathyroid Hormone.

Fukagawa M.

Ther Apher Dial. 2018 Jun;22(3):216-217. doi: 10.1111/1744-9987.12687. No abstract available.

PMID:
29883063
17.

Critical Governance Issue of Parathyroid Hormone Assays and its Selection in the Management of Chronic Kidney Disease Mineral and Bone Disorders.

Kakuta T, Ishida M, Fukagawa M.

Ther Apher Dial. 2018 Jun;22(3):220-228. doi: 10.1111/1744-9987.12690. Epub 2018 May 20. Review.

PMID:
29781225
18.

Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction.

Fujii H, Goto S, Fukagawa M.

Toxins (Basel). 2018 May 16;10(5). pii: E202. doi: 10.3390/toxins10050202. Review.

19.

Emerging Association Between Parathyroid Hormone and Anemia in Hemodialysis Patients.

Tanaka M, Komaba H, Fukagawa M.

Ther Apher Dial. 2018 Jun;22(3):242-245. doi: 10.1111/1744-9987.12685. Epub 2018 May 16. Review.

PMID:
29767854
20.

Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide.

Nakayama M, Tani Y, Zhu WJ, Watanabe K, Yokoyama K, Fukagawa M, Akiba T, Wolf M, Hirakata H.

Kidney Int Rep. 2017 Nov 3;3(2):364-373. doi: 10.1016/j.ekir.2017.10.016. eCollection 2018 Mar.

21.

Secondary Hyperparathyroidism and Protein-Energy Wasting in End-Stage Renal Disease.

Komaba H, Fukagawa M.

Ther Apher Dial. 2018 Jun;22(3):246-250. doi: 10.1111/1744-9987.12683. Epub 2018 Apr 30. Review.

PMID:
29707907
22.

Nutritional status and survival of maintenance hemodialysis patients receiving lanthanum carbonate.

Komaba H, Kakuta T, Wada T, Hida M, Suga T, Fukagawa M.

Nephrol Dial Transplant. 2019 Feb 1;34(2):318-325. doi: 10.1093/ndt/gfy090.

PMID:
29672760
23.

Raltegravir-associated Diabetic Ketoacidosis in a Patient with HIV Infection: A Case Report.

Horikawa M, Toyoda M, Saito N, Kimura M, Kobayashi T, Takagi A, Fukagawa M.

Tokai J Exp Clin Med. 2018 Apr 20;43(1):19-23.

24.

A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.

Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, Hisada Y, Yanagida T, Miyazaki H, Wada M, Akizawa T, Fukagawa M.

PLoS One. 2018 Apr 3;13(4):e0195316. doi: 10.1371/journal.pone.0195316. eCollection 2018.

25.

Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update.

Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB.

Ann Intern Med. 2018 Mar 20;168(6):422-430. doi: 10.7326/M17-2640. Epub 2018 Feb 20.

PMID:
29459980
26.

Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients.

Koiwa F, Yokoyama K, Fukagawa M, Akizawa T.

Kidney Int Rep. 2017 Oct 6;3(1):185-192. doi: 10.1016/j.ekir.2017.10.003. eCollection 2018 Jan.

27.

Interactive Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers or Their Combination on Survival of Hemodialysis Patients.

Kido R, Akizawa T, Fukagawa M, Onishi Y, Yamaguchi T, Fukuhara S.

Am J Nephrol. 2017;46(6):439-447. doi: 10.1159/000482013. Epub 2017 Nov 21.

28.

A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism.

Yokoyama K, Fukagawa M, Shigematsu T, Akiba T, Fujii A, Yamauchi A, Odani M, Akizawa T; ONO-5163 Study Group.

Kidney Int Rep. 2017 Feb 20;2(4):634-644. doi: 10.1016/j.ekir.2017.01.016. eCollection 2017 Jul.

29.

Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate.

Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Otoguro T, Yamada K, Nagamine Y, Fishbane S, Hirakata H.

Kidney Int Rep. 2017 Jan 5;2(3):359-365. doi: 10.1016/j.ekir.2016.12.005. eCollection 2017 May.

30.

[Update on recent progress in vitamin D research. The role of vitamin D in management of CKD-MBD.]

Hamano N, Fukagawa M.

Clin Calcium. 2017;27(11):1609-1614. doi: CliCa171116091614. Japanese.

PMID:
29074834
31.

Magnesium as a new player in CKD: too little is as bad as too much?

Hamano N, Komaba H, Fukagawa M.

Kidney Int. 2017 Nov;92(5):1034-1036. doi: 10.1016/j.kint.2017.05.032.

PMID:
29055421
32.

Adipocytes do not significantly contribute to plasma angiotensinogen.

Koizumi M, Niimura F, Fukagawa M, Matsusaka T.

J Renin Angiotensin Aldosterone Syst. 2016 Oct-Dec;17(4):1470320316672348. doi: 10.1177/1470320316672348.

33.

Erratum to: The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study.

Ogata H, Kumasawa J, Fukuma S, Mizobuchi M, Kinugasa E, Fukagawa M, Fukuhara S, Akizawa T.

Clin Exp Nephrol. 2017 Oct;21(5):809. doi: 10.1007/s10157-017-1459-9. No abstract available.

PMID:
28884458
34.

Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma.

Seki T, Yasuda A, Oki M, Kitajima N, Takagi A, Nakajima N, Miyajima A, Fukagawa M.

Tokai J Exp Clin Med. 2017 Sep 20;42(3):115-120.

35.

Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism.

Watanabe H, Sugimoto R, Ikegami K, Enoki Y, Imafuku T, Fujimura R, Bi J, Nishida K, Sakaguchi Y, Murata M, Maeda H, Hirata K, Jingami S, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Maruyama T.

Biochem Pharmacol. 2017 Dec 1;145:192-201. doi: 10.1016/j.bcp.2017.08.016. Epub 2017 Aug 24.

PMID:
28843775
36.

Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism.

Shigematsu T, Fukagawa M, Yokoyama K, Akiba T, Fujii A, Odani M, Akizawa T; ONO-5163 Study Group.

Clin Exp Nephrol. 2018 Apr;22(2):426-436. doi: 10.1007/s10157-017-1442-5. Epub 2017 Aug 23.

PMID:
28836058
37.

Chronic Kidney Disease-Mineral and Bone Disorder in Asia.

Fukagawa M, Komaba H.

Kidney Dis (Basel). 2017 Jul;3(1):1-7. doi: 10.1159/000470909. Epub 2017 Apr 13. Review.

38.

Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.

Komaba H, Wang M, Taniguchi M, Yamamoto S, Nomura T, Schaubel DE, Smith AR, Zee J, Karaboyas A, Bieber B, Fukagawa M, Tentori F.

Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1489-1497. doi: 10.2215/CJN.13091216. Epub 2017 Jul 19.

39.

Erratum to: The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study.

Ogata H, Kumasawa J, Fukuma S, Mizobuchi M, Kinugasa E, Fukagawa M, Fukuhara S, Akizawa T.

Clin Exp Nephrol. 2017 Oct;21(5):807-808. doi: 10.1007/s10157-017-1439-0. No abstract available.

PMID:
28677097
40.

Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor.

Miyauchi M, Toyoda M, Fukagawa M.

Intern Med. 2017;56(13):1673-1678. doi: 10.2169/internalmedicine.56.7945. Epub 2017 Jul 1.

41.

A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients
.

Yokoyama K, Fukagawa M, Shigematsu T, Akiba T, Fujii A, Odani M, Akizawa T.

Clin Nephrol. 2017 Aug;88(2):68-78. doi: 10.5414/CN108974.

PMID:
28671062
42.

Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.

Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB.

Kidney Int. 2017 Jul;92(1):26-36. doi: 10.1016/j.kint.2017.04.006. Review. Erratum in: Kidney Int. 2017 Dec;92(6):1558.

43.

Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction.

Enoki Y, Watanabe H, Arake R, Fujimura R, Ishiodori K, Imafuku T, Nishida K, Sugimoto R, Nagao S, Miyamura S, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Maruyama T.

J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):735-747. doi: 10.1002/jcsm.12202. Epub 2017 Jun 12.

44.

Uremic Toxicity and Bone in CKD.

Yamamoto S, Fukagawa M.

J Nephrol. 2017 Oct;30(5):623-627. doi: 10.1007/s40620-017-0406-x. Epub 2017 Jun 1. Review.

PMID:
28573386
45.

Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study.

Koiwa F, Yokoyama K, Fukagawa M, Akizawa T.

J Ren Nutr. 2017 Sep;27(5):346-354. doi: 10.1053/j.jrn.2017.02.007. Epub 2017 May 24.

46.

The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study.

Ogata H, Kumasawa J, Fukuma S, Mizobuchi M, Kinugasa E, Fukagawa M, Fukuhara S, Akizawa T.

Clin Exp Nephrol. 2017 Oct;21(5):797-806. doi: 10.1007/s10157-017-1380-2. Epub 2017 May 15. Erratum in: Clin Exp Nephrol. 2017 Jul 4;:. Clin Exp Nephrol. 2017 Sep 7;:.

47.

Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease.

Iwasaki Y, Kazama JJ, Fukagawa M.

Biomed Res Int. 2017;2017:3485785. doi: 10.1155/2017/3485785. Epub 2017 Mar 22. Review.

49.

Resurgence of parathyroidectomy: evidence and outcomes.

Komaba H, Nakamura M, Fukagawa M.

Curr Opin Nephrol Hypertens. 2017 Jul;26(4):243-249. doi: 10.1097/MNH.0000000000000326. Review.

PMID:
28375871
50.

En Bloc Cadaver Kidney Transplantation From a 9-Month-Old Donor to an Adult Recipient: Maturation of Glomerular Size and Podocyte in the Recipient.

Hirukawa T, Suzuki H, Niimura F, Fukagawa M, Kakuta T.

Transplant Direct. 2017 Jan 26;3(3):e130. doi: 10.1097/TXD.0000000000000648. eCollection 2017 Mar.

Supplemental Content

Loading ...
Support Center